Sodium voltage-gated channel alpha subunit 4. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Bupivacaine CHEMBL1098 |
Sodium channel protein type IV alpha subunit blocker Blocker Small molecule |
ChEMBL only | 59 |
| Lidocaine CHEMBL79 |
Sodium channel alpha subunit blocker Blocker Small molecule |
✓ Both | 58 |
| Ropivacaine CHEMBL1077896 |
Sodium channel alpha subunit blocker Blocker Small molecule |
ChEMBL only | 36 |
| Xylocaine CHEMBL1200409 |
Sodium channel alpha subunit blocker Blocker Small molecule |
ChEMBL only | 9 |
| Riluzole CHEMBL744 |
Sodium channel alpha subunit blocker Blocker Small molecule |
ChEMBL only | 7 |
| Carbamazepine CHEMBL108 |
Sodium channel alpha subunit blocker Blocker Small molecule |
ChEMBL only | 6 |
| Mexiletine CHEMBL558 |
Sodium channel alpha subunit blocker Blocker Small molecule |
✓ Both | 5 |
| Phenytoin CHEMBL16 |
Sodium channel alpha subunit blocker Blocker Small molecule |
ChEMBL only | 5 |
| Cenobamate CHEMBL3989949 |
Sodium channel alpha subunit inhibitor Inhibitor Small molecule |
ChEMBL only | 4 |
| Lamotrigine CHEMBL741 |
Sodium channel alpha subunit blocker Blocker Small molecule |
ChEMBL only | 4 |
| Lacosamide CHEMBL58323 |
Sodium channel alpha subunit blocker Blocker Small molecule |
ChEMBL only | 3 |
| Topiramate CHEMBL220492 |
Sodium channel alpha subunit blocker Blocker Small molecule |
ChEMBL only | 3 |
| Levobupivacaine Hydrochloride CHEMBL1200749 |
Sodium channel protein type IV alpha subunit blocker Blocker Small molecule |
ChEMBL only | 2 |
| Prilocaine CHEMBL1194 |
Sodium channel alpha subunit blocker Blocker Small molecule |
ChEMBL only | 2 |
| Ranolazine CHEMBL1404 |
Sodium channel protein type IV alpha subunit blocker Blocker Small molecule |
ChEMBL only | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Headache | 4 | Phase 3 |
| Focal-onset seizure | 3 | Phase 3 |
| Hydrocele testis | 3 | Phase 3 |
| Cesarean section | 3 | Phase 3 |
| Migraine disorder | 3 | Phase 3 |
| Neuropathic pain | 3 | Phase 3 |
| Postherpetic neuralgia | 3 | Phase 3 |
| Chronic pain | 2 | Phase 3 |
| Cough | 2 | Phase 3 |
| Low back pain | 2 | Phase 3 |
| Alcohol dependence | 2 | Phase 3 |
| Bipolar disorder | 2 | Phase 3 |
| Cocaine dependence | 2 | Phase 3 |
| Diabetic neuropathy | 2 | Phase 3 |
| Post-traumatic stress disorder | 2 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
